ENTITY
HUTCHMED

HUTCHMED (HCM US)

56
Analysis
Health Care • Hong Kong
HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing targeted therapies and immunotherapies for cancer and immunological diseases. The company has several novel oncology products marketed in China, with one also approved in the US, Europe, and Japan. HUTCHMED was founded in 2000 and is headquartered in Hong Kong.
more
Exchange Announcement • 09 Jun 2026 18:02

S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Exchange Announcement • 11 Jan 2024 19:02

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 (PDF)

Exchange Announcement • 29 Dec 2023 19:04

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 (PDF)

Exchange Announcement • 21 Dec 2023 19:14

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 (PDF)

Exchange Announcement • 13 Dec 2023 19:04

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 (PDF)

x